AIM Immunotech Inc. (AIM) - 10-K Filing Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: AIM is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its flagship product is Ampligen (rintatolimod), a double-stranded RNA molecule approved in Argentina for Chronic Fatigue Syndrome (CFS) but investigational in the U.S. The company is also developing Alferon N Injection for genital warts, though commercial sales are currently halted due to inventory shortages.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $170,000 | $202,000 |
| Net Loss | $(17,320,000) | $(28,962,000) |
| Loss Per Share (Basic/Diluted) | $(0.31) | $(0.60) |
| Operating Cash Flow | $(14,888,000) | $(21,267,000) |
| Cash & Cash Equivalents | $1,701,000 | $5,439,000 |
| Marketable Securities | $2,276,000 | $7,631,000 |
| Total Liquidity (Cash + Securities) | $3,977,000 | $13,070,000 |
| Working Capital | Deficit of $5,359,000 | Deficit of $5,894,000 |
| Stockholders' Equity | $(1,322,000) | $10,234,000 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $11.6 million (40%) compared to 2023. This was primarily driven by a $7.4 million decrease in General and Administrative (G&A) expenses (due to reduced legal fees from prior year litigation) and a $4.7 million decrease in Research and Development (R&D) expenses.
- Revenue Decline: Revenue decreased by $32,000, attributed to fluctuations in patient participation in the Ampligen Cost Recovery Program.
- Loss of NOL Benefit: The company recognized a $1.6 million loss related to the sale of Net Operating Losses (NOLs) in 2024, compared to a $1.7 million gain in 2023. This shift occurred because the company reached the lifetime cap of $20 million for cumulative NOL sales under the New Jersey Technology Business Tax Certificate Transfer Program.
- Equity Deficit: Stockholders' equity turned negative, dropping from a positive $10.2 million in 2023 to a deficit of $1.3 million in 2024, largely due to the accumulated deficit and the expiration of Series B Preferred Stock.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty: The filing explicitly states that the company's recurring losses, working capital deficit, and negative stockholders' equity raise substantial doubt about its ability to continue as a going concern for one year from the date of issuance. Management is negotiating with vendors to reduce a significant accounts payable balance (approx. $6.4 million, including $4.9 million in legal fees) to alleviate the deficit.
Listing Compliance Risk: AIM is currently non-compliant with NYSE American listing requirements due to stockholders' equity falling below the $6 million minimum. The Exchange accepted a plan to regain compliance by June 11, 2026. Failure to comply could result in delisting. The plan includes a proposed reverse stock split.
Clinical Pipeline Updates:
- Pancreatic Cancer: The Phase 2 study (AMP-270) has been suspended/placed on hold. However, the Erasmus Medical Center approved a Phase 2 study combining Ampligen with Imfinzi (durvalumab).
- Post-COVID Conditions: Final results from the AMP-518 study were posted in January 2025, showing significant improvement in the Six-Minute Walk Test for subjects with moderate-to-severe fatigue.
- Avian Influenza: The company announced plans to pursue a study combining Ampligen with AstraZeneca's FluMist.
Financing Activities: The company entered into an Equity Purchase Agreement with Atlas Sciences, LLC, committing to purchase up to $15 million of common stock over 24 months. As of year-end, approximately $128,000 had been raised under this agreement.
Investor Verification Checklist
- Going Concern Status: Verify the outcome of negotiations regarding the $6.4 million accounts payable, particularly the $4.9 million in legal fees, as this is the primary driver of the working capital deficit.
- Listing Compliance: Monitor the progress of the plan to regain NYSE American compliance, specifically the authorization of the reverse stock split and the ability to raise capital to meet the $6 million equity requirement by June 2026.
- Clinical Trial Status: Confirm the status of the suspended AMP-270 pancreatic cancer trial and the enrollment progress of the new Erasmus Medical Center study.
- Liquidity Runway: Assess whether the current liquidity of ~$4 million is sufficient to fund operations and clinical trials given the lack of material revenue and the cessation of NOL sale proceeds.
- Legal Contingencies: Review the status of ongoing litigation (e.g., Jorgl v. AIM, Kellner v. AIM) and potential financial exposure from judgments or fee awards.